NovImmune
Therapeutic monoclonal antibodies
NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.Founded in 1998
Homepage: http://www.novimmune.com/
Total money raised: $155.4M
Geneva
CHE
CHE
Phone: +41 22 839 71 41
Updated on Dec 17, 2010
NovImmune at CrunchBase
Jack Barbut CEONovImmune at CrunchBase
Penny Ward CMO
Arnd Christ CFO
Marie Kosco-Vilbois CSO
Past
December, 2010
NovImmune raised $20.6M in a Series B round from BZ Bank
NovImmune raises additional CHF 20 million 
novimmune.com
July, 2010
NovImmune inks deal, eyes possible IPO 
fiercebiotech.com
May, 2009
NovImmune raised $54.8M in a Series D round from BZ Bank, Novartis Venture Fund, LODH Immunology Fund, Varuma AG, Pictet Private Equity Investors S.A., Ingro Finanz AG, and Aravis Ventures
NovImmune, SA: Series C $54.8M 
onbiovc.com
June, 2006
NovImmune raised $53M in a Series C round from BZ Bank
Company History novimmune.com
February, 2005
NovImmune raised $13M in a Series B round
Company History novimmune.com
May, 2000
NovImmune raised $14M in a Series A round from Novartis Venture Fund and LODH Immunology Fund
Company History novimmune.com
1998
NovImmune was founded in 1998